Which innovative medicines will lead the Nordic market expansion? In this article, IQVIA Market Prognosis identifies therapies, including anti-obesity treatments poised for significant impact. Read the article to assess our analysis and to identify new growth opportunities. https://bit.ly/4eSs0ik #MarketPrognosis #PharmaInnovation #ObesityTreatments
关于我们
Through our Gold Standard data and analytics, Global Market Insights supports pharmaceutical and life sciences organizations in measuring, managing and segmenting markets, finding and sizing opportunities and maximizing the return on investment across the pharmaceutical drug lifecycle worldwide.
- 网站
-
https://www.iqvia.com
IQVIA Global Market Insights的外部链接
- 所属行业
- 制药业
- 规模
- 超过 10,001 人
- 总部
- Durham，North Carolina
动态
-
Check out the latest #INNsightNewsletter. Explore key opportunities and challenges in the #NordicPharma markets. Discover the latest developments in #mRNA therapies for oncology. Understand the key context for #CMS Prescription Drug Negotiations. Don't miss our on-demand webinar #ChannelDynamics Verbatim with IQVIA #AIAssistant: Transforming #HCPMessageRecall to uncover AI-driven insights that can enhance your 2025 strategy. Click to read and subscribe for future updates!
-
Discover how real-time data and AI are revolutionizing pharma decision-making, enhancing your market responsiveness, and driving success. Read our blog to boost your competitive edge in the rapidly evolving pharma landscape https://bit.ly/49eVbv8 #ChannelDynamicsVerbatim #AIinHealthcare #MarketingStrategy
-
-
IQVIA Global Market Insights转发了
Consultant || Competitive Surveillance & Monitoring || Market Research || Technology Scouting || Innovation Support
I' m excited to share our latest article on the fascinating journey of orphan drug exclusivity in the USA and Europe! The Orphan Drug Act (ODA) of 1983 in the USA and the 2000 Regulation (EC) No. 141/2000 in Europe have been game-changers for rare disease treatments. These laws offer market exclusivity - seven years in the USA and upto twelve years in Europe (upon paediatric approval). Thanks to these regulations, we have seen a boom in approved orphan drugs. Our new article dives deep into the intricacies of orphan drug exclusivity and its impact on the length of protection(LOP), using a biologic drug as a case study. Also a huge shoutout to my amazing team for their unwavering support!!! Check out the full article for more insights.. #Orphandrugs #ODE #Exclusivity #Rarediseases #Orphandrugexclusivity #Healthcare
Orphan Drug Exclusivity: A Lifeline for Rare Disease Patients
iqvia.com
-
Swift, smart, and secure: IQVIA AI Assistant is your new strategic partner in healthcare. Ready to transform your decision-making process? Discover how https://bit.ly/3Zq4TY6 #GenerativeAI #ChannelDynamicsVerbatim Stephen Boyce
-
-
Pharma is ramping up with a 14% boost in sales force investment and a massive 32% increase in conference spending! Discover the dynamics of these initiatives and balance in-person engagement with digital strategies. Get all the insights here. https://bit.ly/49aowqf #PharmaMarketing #PharmaSalesForce
-
-
CASE STUDY: Learn how #PharmaIntelligence revealed unexpected market potential. One company found significant opportunities through data analysis using #MIDASDisease. Could these insights boost your market share? Find out now https://bit.ly/4fWZs97
-
-
Explore how #OrphanDrugsExclusivity (ODE) is driving #DrugInnovation and impacting loss of protection(#LOP). Discover the strategic implications of ODE for pharmaceutical companies and how it reshapes rare disease therapeutics. ODE prevents approval of the same drug for the same disease, even if not relying on the original data. Uncover the opportunities: https://bit.ly/4eJf5ze #ArkPatentIntelligence
-
-
Listen to the voice of the customer. IQVIA ChannelDynamics? Verbatim turns feedback into actionable insights. Ready to accelerate your brand planning? Click here for an exclusive demo! https://bit.ly/4hS8CVH #ChannelDynamicsVerbatim #AIinHealthcare #PharmaIntelligence
-
The report on Use of Medicines in the U.S. 2024 reveals a $5Bn rise in patient out-of-pocket costs in 2023, driven by GLP-1 use for diabetes and obesity. With shifts in co-pay assistance and benefit design, the landscape remains complex: https://bit.ly/3AGFKiu. #MIDASDisease #MarketPrognosis
-